Shares of Fresenius Medical Care AG & Co. KGaA (FMS) surged 7.18% in pre-market trading on Tuesday, following the release of its better-than-expected first-quarter results. The German dialysis company reported quarterly adjusted earnings of 41 cents per share, surpassing analysts' expectations of 38 cents per share, while revenue rose 3.3% to €4.88 billion, also beating the forecasted €4.78 billion.

The company's strong performance was driven by higher demand in its care enablement segment and effective cost discipline. Fresenius Medical Care's net profit also increased, contributing to the positive market reaction. Additionally, the company reiterated its full-year outlook for revenue and operating profit, which further bolstered investor confidence.

Despite the overall positive results, analysts noted that the company's U.S. dialysis treatment growth was flat due to a severe flu season leading to higher mortality among potential patients. However, the stable U.S. market treatment growth and the company's backed outlook are seen as positives by market observers. As Fresenius Medical Care continues to navigate challenges in the healthcare sector, investors appear optimistic about its financial performance and future prospects.